BMY
NYSEBRISTOL MYERS SQUIBB CO
Health Care, Pharmaceuticals
$64.72
close 7 Aug 2026
+40.91%
52-week change
$132.20B
market cap
$42.52
$68.10
52-week range
Valuation
Market cap$132.20B
P/E (TTM / 5y avg)14.22x18.90x
Forward P/E (FY2026 / FY2027)9.32x9.88x
PEG (TTM / fwd)2.61—
P/S (TTM)2.69x
P/B5.92x
EV/EBITDA (TTM)9.66x
FCF yield (TTM)8.65%
Cash flow & dividend
FCF (TTM)$11.44B
FCF per share (TTM)$5.60
FCF margin (TTM)23.26%
Dividend yield (indicated / 5y avg)3.89%4.08%
Annualized dividend$2.52
Payout ratio (EPS / FCF)54.89%44.54%
Growth & quality
Revenue YoY, latest Q+5.74%
Diluted EPS YoY, latest Q+153.13%
Operating margin (TTM)—
Net margin (TTM)18.87%
ROE (latest FY)38.19%
Net debt / EBITDA (TTM)1.98
Interest coverage (TTM)—
Price
-4.13%-0.84%/yrover 5y
Weekly closes · split-adjusted
close 7 Aug 2026
Fundamentals
Fiscal years, last 10, CAGR chips on growth series, plus a dimmed trailing-twelve-month bar
Revenue
5Y CAGR +2.54%10Y CAGR +11.27%
Diluted EPS
10Y CAGR +14.04%
FCF per share
5Y CAGR +1.37%10Y CAGR +23.50%
Operating cash flow
5Y CAGR +0.15%10Y CAGR +21%
Free cash flow
5Y CAGR -0.69%10Y CAGR +25.89%
Dividends per share
5Y CAGR +6.53%10Y CAGR +5.33%
Payout ratio
FCF payout ratio
FCF margin
Return on equity
Shares outstanding
5Y CAGR -2.03%10Y CAGR +1.94%
Net debt / EBITDA
Earnings
Street estimates, not SEC filings
Next / Q3 FY26
Date29 Oct 2026
EPS estimate$1.62
Revenue estimate$12.19B
Last reported
Date—
EPS——
Revenue——